Ludwig Enterprises, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ludwig Enterprises, Inc. operates as a biotech and healthcare holding company headquartered in Miami, Florida, founded in 1988. The company develops and provides genomic and medical technology products that utilize mRNA genetic biomarkers to detect inflammatory genetic markers associated with inflammation-driven diseases, including cancer and heart disease. Its core offerings include the Revealia for Life Home Test Kits, which use a non-invasive, two-minute cheek swab for early screening of multiple cancers and other chronic inflammatory diseases, enabling convenient at-home health monitoring without invasive procedures. The company's product pipeline focuses on innovative medical machine learning and artificial intelligence technology that uses mRNA inflammatory language to capture real-time inflammatory snapshots for disease detection and treatment response monitoring. Recent major changes at Ludwig Enterprises include accelerated clinical validation and PCR test process for its breast cancer screening program, Revealia™, with an anticipated product launch in the fourth quarter of 2024. The company has initiated partnerships with independent laboratories for validation and has published significant scientific abstracts in leading oncology journals. In 2025, leadership changes occurred including the appointment of Jose Antonio Reyes as interim CEO. Ludwig is actively expanding its cancer screening business while leveraging patented mRNA screening technology and pursuing additional clinical validation papers and advisory board expansions. Financially, Ludwig Enterprises is transitioning from research and development toward anticipated product sales revenue in late 2025, contingent on successful funding and regulatory approvals. Subsidiaries include Precision Genomics, Inc. and MyRNA for Life, Inc., supporting its broad healthcare and genomic technology platform within the United States market.
Ludwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast Cancer
Revealia Breast(TM) Offers Glimpse Into the Future of Early Cancer Detection With a Simple Cheek Swab
Ludwig Enterprises Announces Two Abstracts Accepted for Publication in the Journal of Clinical Oncology
Ludwig Enterprises Inc. Announces New Leadership Appointment of Charles T. Todd, Jr.
Ludwig Enterprises Begins PCR Validation Test Process
Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
CORRECTING AND REPLACING: Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
Ludwig Announces Acquisition of Intellectual Property and Patent
Nova Mentis Assigns Intellectual Property
Ludwig Announces Substantial Corporate Initiatives
Ludwig Enterprises Files Provisional Patent on mRNA Genetic Screening Signals in Breast, Colon and Bladder Cancer
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Exousia AI Ludwig Enterprises Subsidiary Launches Liposome Research Program
Ludwig Enterprises Appoints Scott Silverman as CFO
Ludwig Enterprises Announces Effectiveness of Form S-1 Registration Application, Becomes an SEC Reporting Company